Austin, TX – [Date, e.g., October 26, 2023] – Hanger Inc., a leading national provider of orthotic and prosthetic (O&P) patient care services and solutions, has announced a pivotal acquisition set to significantly bolster its research and innovation capabilities. The company has successfully acquired Liberating Technologies Inc. (LTI), a renowned research organization with a distinguished track record in developing next-generation prosthetic technologies. This strategic move underscores Hanger’s unwavering commitment to advancing clinical practice, expanding its research and development footprint, and ultimately enhancing the lives of O&P patients through groundbreaking, evidence-based care.
The integration of LTI into the Hanger ecosystem is poised to accelerate the development of cutting-edge solutions, addressing critical needs in the O&P field, from advanced prosthesis control mechanisms to vital improvements in residual limb health and user comfort. This acquisition, following Hanger’s earlier announcement regarding the acquisition of LTI’s former parent company, Coapt, solidifies Hanger’s position at the forefront of prosthetic innovation, bringing a full suite of advanced technologies and research expertise under its expansive umbrella.
Main Facts: Hanger Inc. Bolsters Innovation with Strategic Acquisition of Liberating Technologies Inc.
In a significant development for the orthotics and prosthetics industry, Hanger Inc., a dominant force in O&P patient care, has announced the successful acquisition of Liberating Technologies Inc. (LTI). This move, publicly communicated by Hanger Inc. via its corporate channels, signifies a calculated effort to deepen the company’s commitment to research and development, a cornerstone of its long-term strategy for improving patient outcomes.
Liberating Technologies Inc., founded in 2000, has established itself as a specialized research organization dedicated to pushing the boundaries of prosthetic technology. Prior to this acquisition, LTI operated under the ownership of Coapt, a company whose full portfolio Hanger Inc. has now absorbed. Since 2008, LTI’s expert team has been a consistent recipient of numerous government-funded grants, a testament to its innovative capacity and the high-impact nature of its research. These grants have enabled LTI to pursue ambitious, cutting-edge concepts aimed at developing revolutionary technologies for the O&P sector.
The primary objective behind Hanger’s acquisition of LTI is multifaceted: to strengthen its internal research and innovation capabilities, accelerate the pace of development for next-generation prosthetic technologies, and ensure that advancements in the field directly translate into tangible improvements in patient care and quality of life. This strategic alignment promises to foster an environment where scientific inquiry meets practical application, ultimately benefiting the thousands of individuals who rely on orthotic and prosthetic devices daily.
Pete Stoy, Hanger’s Chief Executive Officer, articulated the profound significance of this acquisition. "The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," Stoy stated. His remarks underscored the company’s strategic vision, which extends beyond service provision to active participation in shaping the future of O&P technology. He further emphasized, "This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation." This statement highlights Hanger’s intent to leverage LTI’s expertise not just internally, but also as a catalyst for broader industry collaboration and advancement.
LTI will now be integrated into Hanger’s formidable innovation infrastructure, joining Hanger Ventures and the esteemed Hanger Institute for Clinical Research and Education. This integration is designed to create a synergistic environment where LTI’s specialized research talents can flourish, supported by Hanger’s extensive clinical insights, technical resources, and vast patient data. The LTI team is slated to continue leading its existing grant-funded initiatives, which include pivotal projects focused on voice-recognition technology for enhanced prosthesis control, the development of sophisticated socket cooling systems for residual limb skin health, and the optimization of electrode configurations for pattern recognition control to achieve superior functional outcomes for prosthesis users. Simultaneously, the team will actively pursue new research and development opportunities, ensuring a continuous pipeline of innovation.
A Legacy of Innovation: The Journey of Liberating Technologies Inc.
Liberating Technologies Inc. (LTI) has, for over two decades, been a quiet but powerful force in the realm of advanced prosthetic research. Founded in the year 2000, LTI was established with a clear mandate: to push the technological boundaries of human-device interfaces and improve the functional capabilities of individuals with limb loss. From its inception, the organization distinguished itself through a dedicated focus on scientific rigor and an unwavering commitment to high-impact research.
A significant turning point in LTI’s trajectory came in 2008, when its specialized research team began consistently securing government-funded grants. These grants, originating from various federal agencies and defense departments, are notoriously competitive and are typically awarded only to projects demonstrating exceptional scientific merit, feasibility, and potential for transformative impact. The continuous stream of funding not only validated LTI’s research methodologies and innovative concepts but also provided the necessary resources to translate ambitious ideas into tangible prototypes and solutions.
LTI’s research portfolio has been characterized by its forward-thinking approach, often tackling challenges that others deemed too complex or nascent. Their work has consistently aimed at addressing fundamental limitations in existing prosthetic technologies, focusing on areas that directly impact the user’s experience and functional independence. This has included pioneering efforts in areas such as intuitive control systems, sensory feedback mechanisms, and advanced materials science, all with the ultimate goal of making prostheses feel and function more like natural limbs.
Under its previous ownership by Coapt, LTI operated as a vital research arm, contributing to Coapt’s own advancements in myoelectric control systems. This symbiotic relationship allowed LTI to maintain its research focus while benefiting from Coapt’s commercialization efforts in specific product lines. The intellectual property and accumulated expertise within LTI represent a treasure trove of scientific discovery and engineering prowess, making it a highly attractive asset for a patient-care focused organization like Hanger Inc. The organization’s legacy is not just one of scientific papers and patents, but of laying the groundwork for technologies that promise to fundamentally change how individuals interact with their prosthetic devices and, by extension, the world around them.
Strategic Rationale: Why Hanger Made the Move
Hanger Inc.’s acquisition of Liberating Technologies Inc. is far from a mere expansion; it is a calculated strategic maneuver designed to solidify the company’s leadership position in a rapidly evolving healthcare landscape. The decision reflects a deep understanding of the current and future needs within the orthotics and prosthetics sector, where technological advancement is increasingly intertwined with superior patient care.
At its core, Hanger’s mission revolves around improving patient outcomes through evidence-based care. While Hanger already boasts an extensive network of O&P clinics and a significant market presence, direct and robust engagement in cutting-edge research is crucial for continuous innovation. The acquisition of LTI directly addresses this need by bringing in a proven team of researchers and an established pipeline of grant-funded projects. This immediately amplifies Hanger’s capacity to explore and develop novel solutions that can be rigorously tested and integrated into clinical practice.
Pete Stoy’s commentary on the acquisition provides crucial insight into Hanger’s strategic vision. His emphasis on "expanding research and development, advancing clinical practice, and improving patient outcomes" highlights a holistic approach. It’s not just about creating new devices, but about systematically enhancing the entire continuum of care. By bringing LTI’s research capabilities in-house, Hanger gains direct control over the innovation cycle, allowing for faster translation of scientific discoveries into clinically relevant applications. This vertical integration of research and patient care is a powerful differentiator in the O&P market.
Furthermore, Stoy’s ambition to "accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation" speaks to Hanger’s broader industry leadership aspirations. The company recognizes that groundbreaking advancements often emerge from collaborative ecosystems. LTI’s history of securing government grants and engaging in specialized research positions Hanger to attract further external funding and foster partnerships with academic institutions, government bodies, and other industry players. This positions Hanger not just as a consumer of innovation, but as a key driver and facilitator of it on a global scale.
The synergistic potential between LTI and Hanger’s existing innovation infrastructure, namely Hanger Ventures and the Hanger Institute for Clinical Research and Education, is immense. Hanger Ventures is dedicated to identifying, investing in, and developing emerging technologies that align with Hanger’s mission. The Hanger Institute, on the other hand, is a cornerstone for clinical research, education, and the dissemination of best practices among O&P professionals. LTI’s integration means its research projects will now have direct access to a vast network of clinicians, a rich repository of clinical data, and the real-world insights derived from thousands of patient interactions across Hanger’s clinics nationwide. This immediate feedback loop between researchers and practitioners is invaluable, ensuring that new technologies are not only scientifically sound but also clinically practical and patient-centric.
In essence, Hanger’s acquisition of LTI is a strategic investment in its future, cementing its role not just as a provider of O&P services, but as a proactive innovator and thought leader dedicated to fundamentally improving the lives of individuals with limb loss through cutting-edge science and technology.
Chronology: A Planned Integration and Expanding Portfolio
The acquisition of Liberating Technologies Inc. (LTI) by Hanger Inc. is not an isolated event but rather the culmination of a broader strategic initiative that began some time ago. This latest development represents a significant step in Hanger’s systematic expansion of its technological capabilities and the strategic consolidation of key innovative players within the orthotics and prosthetics space.
The foundational piece of this chronology was laid out in 2025, when Hanger Inc. publicly announced its impending acquisition of Coapt. Coapt, a company renowned for its advanced myoelectric control systems for upper-limb prosthetics, had previously acquired Liberating Technologies Inc. This meant that LTI, while a distinct research entity, was operating as a subsidiary under the Coapt umbrella. Hanger’s initial move to acquire Coapt was a clear signal of its intent to bring sophisticated prosthetic control technologies directly into its service offerings and research ecosystem.
The current announcement regarding the direct acquisition of LTI completes this strategic puzzle. With the integration of LTI, Hanger now encompasses the "full Coapt portfolio." This phrase is critical, as it implies that Hanger has not just acquired a product line or a company, but has absorbed the entire intellectual capital, research capabilities, and technological pipeline associated with Coapt and its subsidiary. This provides Hanger with a comprehensive suite of advanced prosthetic solutions, from cutting-edge control algorithms to the fundamental research that underpins future innovations.
The integration process for LTI is carefully planned to maximize synergy and maintain research momentum. LTI will not be dissolved but rather integrated as a specialized unit within Hanger’s robust innovation framework. Specifically, it will join Hanger Ventures, the company’s investment arm focused on emerging technologies, and the Hanger Institute for Clinical Research and Education. This structural placement is strategic. Hanger Ventures provides the necessary infrastructure and strategic guidance for commercialization and scaling of innovative solutions, while the Hanger Institute offers unparalleled access to clinical expertise, patient data, and a network of O&P professionals who can provide invaluable real-world feedback on emerging technologies.
By bringing LTI into these established frameworks, Hanger ensures that the research team retains its focus on innovation while benefiting from the broader organizational support, resources, and clinical validation that Hanger provides. This planned integration allows LTI to continue its critical grant-funded initiatives without interruption, while simultaneously opening new avenues for collaboration and accelerating the translation of research findings into practical applications for patients. The chronology thus reflects a deliberate, multi-stage strategy by Hanger to progressively enhance its technological prowess and leadership in the O&P industry.
Supporting Data: The Cutting Edge of Prosthetic Development
The value of Liberating Technologies Inc. (LTI) to Hanger Inc. is most vividly illustrated by the specific, cutting-edge research initiatives that LTI has been spearheading. These projects represent the vanguard of prosthetic technology, addressing critical challenges faced by users and promising to deliver significant improvements in function, comfort, and overall quality of life. LTI’s ongoing grant-funded initiatives provide a tangible glimpse into the future of orthotics and prosthetics.
One of the cornerstone projects involves advancing voice-recognition technology for improved prosthesis control. Current prosthetic control systems, particularly for upper-limb devices, often rely on myoelectric signals (muscle contractions) or physical switches. While effective, these methods can be cumbersome, require significant training, and may not offer the intuitive, nuanced control that users desire. Voice recognition offers a potentially revolutionary alternative. Imagine a prosthesis user being able to simply say "grasp" or "release" to control their device, or even more complex commands like "pick up pen" or "hold glass." LTI’s research in this area focuses on developing robust, reliable, and context-aware voice control algorithms that can interpret a user’s intent with high accuracy, even in noisy environments. This technology promises to reduce cognitive load, increase the speed and fluidity of prosthetic movements, and empower users with a more natural and direct interface to their devices, significantly enhancing their independence and interaction with their environment.
Another critical area of LTI’s research is the development of socket cooling systems to support residual limb skin health. The prosthetic socket, which interfaces directly with the residual limb, is a crucial but often problematic component. Issues such as heat buildup, sweating, friction, and pressure can lead to skin breakdown, discomfort, pain, and even infection, forcing users to remove their prostheses for extended periods. This directly impacts their mobility and quality of life. LTI’s work in socket cooling aims to mitigate these issues by designing integrated systems that can actively regulate temperature and manage moisture within the socket. This could involve innovative materials, miniature thermoelectric devices, or advanced ventilation designs. The impact of successful socket cooling systems would be profound: increased wear time, reduced incidence of skin complications, improved comfort, and ultimately, greater functional independence for prosthetic users. This research is vital for long-term limb health and sustained prosthesis use.
Finally, LTI is dedicated to optimizing electrode configurations for pattern recognition control to help prosthesis users achieve optimal functional outcomes. Pattern recognition is a sophisticated method of interpreting myoelectric signals from multiple muscles in the residual limb to predict a user’s intended movement. While highly promising, its effectiveness can be significantly influenced by the placement and configuration of electrodes, as well as the robustness of the algorithms used to interpret the signals. LTI’s research delves into refining these aspects, exploring novel electrode designs, placements, and signal processing techniques to improve the accuracy, reliability, and intuitiveness of pattern recognition systems. The goal is to enable prosthesis users to control their devices with a fluidity and precision that more closely mimics natural limb movement, allowing for a wider range of functional tasks and a more seamless integration of the prosthesis into daily life. This involves advanced machine learning, signal processing, and a deep understanding of neurophysiology.
These initiatives, fueled by continuous government grants, demonstrate LTI’s commitment to tackling complex problems with innovative solutions. By bringing these projects under the Hanger Inc. umbrella, the research will now benefit from direct access to extensive clinical data, real-world patient feedback, and the resources of a leading O&P provider, accelerating the translation of these cutting-edge concepts into widely available, life-changing technologies.
Official Responses: Voices from the Leadership
The official statements from Hanger Inc.’s leadership provide profound insights into the strategic rationale and envisioned future following the acquisition of Liberating Technologies Inc. These responses are not merely corporate announcements but rather a declaration of Hanger’s enhanced commitment to innovation and patient-centric care.
Pete Stoy, Hanger’s Chief Executive Officer, articulated the company’s overarching vision with clarity and conviction. His statement, "The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," is particularly telling. It highlights a three-pronged strategic focus:
- Expanding R&D: This signifies a proactive stance, moving beyond incremental improvements to actively seeking disruptive innovations. It implies a significant investment in scientific inquiry and technological exploration.
- Advancing Clinical Practice: The goal is not just to develop new technologies but to ensure they are effectively integrated into clinical settings, leading to superior treatment protocols and care delivery. This emphasizes the critical link between research and practical application.
- Improving Patient Outcomes through Evidence-Based Care: This is the ultimate objective. Stoy’s words underscore Hanger’s dedication to solutions that are not only innovative but also clinically validated, ensuring they deliver measurable benefits to patients. This commitment to evidence-based care reinforces trust and quality in the services provided.
Stoy further elaborated on Hanger’s broader aspirations: "This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation." This statement positions Hanger not just as a domestic leader but as a global catalyst for change. It signals an openness to collaboration, recognizing that complex problems require diverse expertise. By integrating LTI, Hanger gains an established research team with a history of successful grant acquisitions, making it a more attractive partner for other innovators, academic institutions, and funding bodies worldwide. This ambition to drive "the next generation of innovation" suggests a long-term vision focused on foundational advancements that will shape the future of the O&P industry.
Todd Farrell, PhD, who serves as Vice President of Research and Development for Hanger, provided the perspective from the innovation front lines, highlighting the immediate benefits for LTI. "We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation," Farrell stated. His enthusiasm is rooted in the practical advantages that LTI gains:
- Technical Resources: Hanger’s extensive infrastructure, ranging from advanced manufacturing capabilities to sophisticated data analytics platforms, will now be at LTI’s disposal. This can significantly accelerate prototyping, testing, and refinement processes.
- Access to Clinical Insights: This is arguably one of the most invaluable assets. Hanger’s vast network of O&P clinicians interacts with thousands of patients daily, generating a wealth of qualitative and quantitative data on user needs, challenges, and preferences. LTI researchers can tap into this knowledge directly, ensuring their innovations are relevant, practical, and truly address real-world problems. This direct feedback loop is crucial for developing user-centric technologies.
- Clinical Data: Beyond anecdotal insights, Hanger possesses an extensive repository of clinical data, including patient outcomes, device performance metrics, and rehabilitation progress. This data is essential for validating research findings, identifying new research avenues, and demonstrating the efficacy of new technologies in real-world scenarios.
Farrell’s comments emphasize the synergistic nature of the acquisition, where LTI’s research prowess is enhanced by Hanger’s extensive clinical reach and operational capabilities. The "Hanger ecosystem" becomes a powerful engine for translating scientific discovery into practical, patient-benefiting solutions, a truly integrated approach to innovation.
Implications for the Future of Orthotics and Prosthetics
The acquisition of Liberating Technologies Inc. by Hanger Inc. carries profound implications that will resonate throughout the orthotics and prosthetics industry, influencing patient care, technological trajectories, and Hanger’s market standing for years to come.
Enhanced Patient Outcomes and Quality of Life
The most direct and significant implication is the potential for vastly improved patient outcomes and an elevated quality of life for individuals with limb loss. LTI’s research, particularly in areas like voice-recognition control, socket cooling, and optimized pattern recognition, addresses fundamental challenges that impact daily living. More intuitive control systems mean less frustration and greater independence. Cooler, healthier residual limbs mean less pain, fewer complications, and longer wear times, translating to increased mobility and participation in daily activities. Ultimately, these advancements aim to make prostheses feel less like tools and more like extensions of the body, fostering greater confidence and integration for users. Hanger’s ability to quickly translate LTI’s innovations from research labs to clinical application, supported by its extensive network, means these benefits could reach a wide patient population faster than ever before.
Accelerating Technological Advancement
This acquisition is set to significantly accelerate the pace of technological advancement within the O&P field. By integrating LTI’s specialized research capabilities with Hanger’s clinical insights and resources, a powerful innovation engine is created. The traditional gap between academic research and commercial application often slows down progress. Hanger’s integrated model aims to bridge this gap, allowing for rapid prototyping, rigorous clinical testing, and efficient deployment of new technologies. This could inspire other industry players to increase their own R&D investments, fostering a competitive environment that drives overall innovation for the benefit of patients globally. Hanger’s expressed ambition to "accelerate global technological progress" suggests a leadership role in setting new benchmarks for prosthetic capabilities.
Strengthening Hanger’s Market Position
For Hanger Inc., this acquisition undeniably strengthens its market position as a leader in both O&P patient care and innovation. In an increasingly competitive healthcare landscape, differentiation through superior technology and patient outcomes is crucial. By owning the full Coapt portfolio, including LTI’s foundational research, Hanger gains a proprietary advantage in advanced prosthetic control and related technologies. This not only enhances its service offerings but also attracts top talent in research and clinical practice. It positions Hanger as a forward-thinking, science-driven organization, capable of shaping the future of the industry rather than merely responding to its trends. This strategic move cements Hanger’s reputation as a comprehensive solutions provider, from initial patient consultation to the deployment of the most advanced prosthetic technologies.
The Role of Collaboration and Funding
LTI’s history of securing government-funded grants highlights the crucial role of external funding in driving high-impact research. Hanger’s acquisition not only allows LTI to continue these initiatives but also positions Hanger as an attractive partner for future government, academic, and private collaborations. The synergy between Hanger’s clinical reach and LTI’s research acumen could unlock new funding opportunities for projects that require large-scale clinical validation or data collection. This could lead to a virtuous cycle where successful grant-funded research translates into improved patient care, which in turn strengthens Hanger’s ability to secure further funding and partnerships.
Challenges and Opportunities Ahead
While the implications are largely positive, challenges remain. Integrating a specialized research organization into a larger corporate structure requires careful management to preserve LTI’s innovative culture and scientific independence. Ensuring seamless data sharing, intellectual property management, and resource allocation will be critical. Furthermore, translating complex research into commercially viable and widely accessible products always presents hurdles, including regulatory approvals, manufacturing scalability, and clinician training.
However, the opportunities far outweigh these challenges. The acquisition opens doors to entirely new research avenues, such as advanced sensory feedback systems, brain-computer interfaces, and personalized prosthetic designs driven by artificial intelligence. By combining LTI’s expertise with Hanger’s extensive clinical network and resources, Hanger is uniquely positioned to explore these frontiers, ushering in an era of unprecedented progress in orthotics and prosthetics. The future promises prostheses that are more intuitive, comfortable, and functionally integrated, ultimately empowering individuals with limb loss to lead fuller, more active lives.
In conclusion, Hanger Inc.’s acquisition of Liberating Technologies Inc. is a landmark event, signaling a powerful commitment to innovation, patient-centric care, and industry leadership. It represents a bold step towards a future where the boundaries of prosthetic technology are continually pushed, transforming the lives of patients and redefining the possibilities of human potential.
